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Implementation of Xpert MTB/RIF for routine point-of-care 
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Kate Clouse, Liesl Page-Shipp, Heather Dansey, Bridgette Moatlhodi, Lesley Scott, Jean Bassett, 
Wendy Stevens, Ian Sanne, Annelies Van Rie
In December 2010, the WHO endorsed Xpert MTB/RIF (Cepheid, 
Sunnyvale, CA, USA) as a first-line diagnostic for TB in patients 
suspected of HIV-associated TB or multidrug-resistant (MDR) TB.1 
South Africa, the first country to roll out the assay, opted to place 
the instruments at centralised microscopy centres and reference 
laboratories of the National Health Laboratory Service, mainly owing 
to cost considerations and to allow rapid roll-out.2
Xpert MTB/RIF (Xpert)’s short turnaround time and simplicity 
raised potential for point-of-care (POC) use.3,4 The motivation for 
POC technology (be it HIV, CD4 or TB testing) is to provide same-
day results, hasten treatment initiation, and avoid loss to follow-up 
during the diagnostic process. Little is known about POC use of 
Xpert at primary healthcare level, and operational research is needed 
before its use at the peripheral level can be recommended.3,5
In July 2011, we launched Xpert as the initial, routine, POC 
diagnostic for all TB suspects at Witkoppen Health and Welfare 
Centre, a high-volume (8 500 monthly visits), NGO-operated primary 
care clinic. The centre serves residents of informal settlement areas 
within northern Johannesburg that have a high HIV and TB burden. 
Human resource requirements
Human resource requirements were greater than anticipated, because 
the use of Xpert increased the number of TB cases identified and 
because staff time per TB suspect assessed was higher than expected. 
While Xpert is in principle a 2-hour test,6 this only refers to the 
assay turnaround time. Registering clients in the TB suspect register, 
educating them on providing a quality sputum, adding the buffer, 
processing the sample, transferring the sample into the cartridge, and 
transporting the cartridge to the instrument, all require personnel 
and time. Once the assay is ready, the results must be printed and 
filed and the patient traced within the clinic and referred to the next 
clinic service, depending on the Xpert result and reason for visit. 
Consequently, while we expected to need 1 full-time employee, 
we found we needed a minimum of 2 full-time employees to ensure 
operation of POC Xpert services for an average of 16 TB suspects 
(range: 7 - 29) daily. The clinic opted to employ 2.5 full-time staff 
to ensure continuous POC Xpert service: 1 person at the outdoor 
sputum booth for patient assistance, sample buffering and data entry 
in the suspect register; 1 in the Xpert instrument room to perform the 
Xpert MTB/RIF (Xpert) offers rapid detection of Mycobacterium 
tuberculosis and rifampicin resistance. However, little is known 
about routine point-of-care (POC) use in high TB/HIV burden 
settings. We describe our experiences of launching Xpert as the 
POC, initial diagnostic for all TB suspects at a primary healthcare 
clinic in Johannesburg, South Africa. Noted important benefits 
of POC Xpert were fewer clinic visits, rapid detection of TB 
and rifampicin resistance, real-time assessment of accompanying 
household members of new TB cases, and increased staff motivation 
for TB screening. 
While Xpert results are available within 2 hours, actual turn-
around time was longer for most patients because of sample 
preparation time and clinic congestion. Consequently, a GX4 
instrument did not result in a 16-test capacity during an 8-hour 
working day, and some patients did not receive same-day results. 
Loss to follow-up was an unforeseen challenge, overcome by clinic 
flow changes, marking of clinic files, documenting patients’ physical 
description and locating patients in the clinic by cell phone. Staff 
with high school education successfully performed the assay after 
minimal training. 
Human resource requirements were considerable, with a 
minimum of 2 staff needed to supervise sputum collection, process 
sputum, perform assays, and document results for an average of 15 
TB suspects daily. POC placement of the instrument transferred 
logistical responsibilities to the clinic, including quality assurance, 
maintenance, stock control and cartridge disposal.
POC use of Xpert is feasible at the primary healthcare level 
but must be accompanied by financial, operational and logistical 
support.
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assay, communicate results to patients and healthcare workers and 
capture data in clinic file and TB registers; and a third person at 50% 
effort for assistance during the busy afternoon period and to cover for 
lunch breaks and absences. In addition, 1 low-skilled runner carries 
buffered sputum samples between the outdoor sputum collection 
booth and the instrument room and traces patients within the clinic. 
This ‘POC Xpert team’ was employed in addition to the existing 
clinic TB team, which consists of 1 part-time physician, 1 full-
time nurse and 2 full-time auxiliary nurses. Specialised skills were 
not required, as staff with high school education and no formal 
laboratory training performed the Xpert assay after 2 days of 
training. 
Instrument requirements
According to the WHO, the four-module Xpert instrument has a 
capacity of 15 - 20 tests per working day.7 While this is probably 
a correct estimate for instruments placed in a laboratory, 2 four-
module instruments were required to process an average of 15 
samples daily at POC. Even though the clinic operates 8 hours daily, 
the first sputum sample is only available 2 - 3 hours after the first 
TB suspect arrives at the clinic, as clients proceed through several 
administrative and care steps before sputum is collected. The last 
time a cartridge can be loaded and provide a same-day result is 2 
or preferably 3 hours before the clinic closes. Tests for patients who 
present late in the day are run overnight and results are available the 
following day. In addition, tests resulting in errors or invalid results 
need to be repeated. We observed an error or invalid rate of 3.4%, 
consistent with the 2.4 - 5.9% observed elsewhere.8,9 
Infrastructure requirements
TB testing at POC, outside of the laboratory, requires emphasis 
on infection control and biosafety. An outdoor sputum booth was 
constructed to provide adequate ventilation, and this is where sputum 
collection is performed and the Xpert buffer added. Clinic staff 
are instructed to wear N-95 masks when collecting and buffering 
sputum, and when communicating face-to-face with TB suspects. 
New TB cases are asked to wear surgical masks. Conditions for 
instrument operation within the clinic were also optimised, ensuring 
a temperature <30°C, stable electrical supply, connection of the 2 
instruments to 1 computer, security measures against theft, and 
adequate storage space for the cartridges.
Changing the clinic flow and 
optimising patient retention
In contrast to our expectations, many patients initially failed to 
receive their Xpert result because they had left the clinic or were 
untraceable within the clinic 2 hours after the cartridge was placed 
in the instrument. To overcome this problem many interventions 
requiring co-operation from the entire clinic have been implemented. 
First, a paper slip identifying the TB suspect as receiving an 
Xpert assay is stapled to the outside of the clinic file and only 
removed once the patient receives the result. This allows the 
patient to attend other clinic services while the assay is running, 
and prevents the clinic from unknowingly checking out the 
patient before they receive their results. It also serves to alert the 
clinician that the patient has been identified as a TB suspect and 
is currently awaiting Xpert results. Second, the TB suspect’s cell 
phone number is recorded (when available) and the number is 
tested on the spot to ensure it is correct and the phone is turned 
on. When the test is completed, a text message is sent: ‘Your TB 
results are ready. Please come to the TB Room.’ Third, a physical 
description of each TB suspect is recorded, including the colour of 
clothing worn. When the TB suspect cannot be reached by phone, 
runners are deployed to help locate patients in the clinic using 
this description. 
Since these measures were implemented, TB suspects have received 
their test result on the same day, except for those who need to leave 
the clinic for work purposes and those who provide a sputum sample 
<2 hours before the clinic closes. 
The aim of rapid POC technology is to receive a same-day test 
result and to act upon it in real-time. When diagnosis is based on 
smear microscopy, TB suspects provide a sputum sample and come 
back a few days later. At the second visit, they arrive in the morning 
and have results ready in their file, and the nurse or clinician can 
start TB treatment immediately. In contrast, when using Xpert at 
POC, new cases of TB are identified throughout the day. Staff must 
therefore be ready to register a new case and initiate treatment at any 
time, even at the end of the workday. 
Furthermore, when provided with Xpert at POC, TB suspects 
continue their clinic visit while the sample is being processed. 
However, the results of the Xpert assay may not yet be ready, creating 
the need for 2 consultations on the same day, once before and once 
after the Xpert results are available. Since the vast majority of TB 
suspects are Xpert negative, the clinic opted to presumptively manage 
TB suspects as Xpert negative and schedule a follow-up visit 1 week 
later. Consequently, only clients with a positive Xpert result may need 
to be seen twice by a healthcare worker on a single day or traced to 
begin TB treatment.
Shifting responsibilities from 
laboratory to clinic
Positioning Xpert instruments at POC in the clinic has management 
and cost implications beyond the purchase of the instrument and 
cartridges required for processing samples. Increased overhead and 
management costs include instrument insurance, decentralised billing, 
cartridge procurement and stock control, and data management to 
ensure results are linked to a national TB database. POC laboratories 
also require consistent electricity, regular maintenance and calibration 
of the instruments, staff training, certification, and participation in 
external quality assurance programmes.
Anticipated and unanticipated 
benefits of POC Xpert 
As expected, placing Xpert at POC resulted in increased case 
detection, same-day treatment initiation in over 80% of new cases, 
and knowledge of the M. tuberculosis strain’s susceptibility to 
rifampicin on the day that treatment is started. 
In addition, we discovered some unanticipated benefits. Clinic 
staff were enthusiastic about the possibility of a same-day result, 
which increased their motivation to identify TB suspects. Clinicians 
especially valued the ability to rapidly assess rifampicin resistance 
among patients not responding to treatment. Awareness of on-site 
rapid TB testing led clinic staff to request a TB test for themselves 
when symptomatic. Additionally, the same-day availability of results 
enabled real-time TB contact identification when a new case was 
accompanied by a partner or relatives. 
Conclusion
While our results were overwhelmingly positive, our experiences 
highlight that the infrastructure, instrument and human resource 
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Severe anaemia is a major cause of paediatric hospital admissions 
and deaths in many African countries, with a hospital prevalence of 
10 - 30% and case fatality rates between 4 and 10%.1,2 Anaemia, in 
which blood oxygen carrying capacity is reduced, is characterised by 
a low haemoglobin concentration.3 The World Health Organization 
(WHO) defined severe anaemia in patients with malaria as a 
haemoglobin concentration less than 50 g/l.3Anaemia becomes life-
threatening when affected individuals develop complications such 
as heart failure, metabolic acidosis and hypoxic encephalopathy.4
Severe falciparum malaria remains the leading cause of 
paediatric anaemia in sub-Saharan Africa.1,2,4 Anaemia may 
develop in children already debilitated by other conditions such 
as nutritional deficiencies, bacteraemia, human immunodeficiency 
viral (HIV) infections, haemoglobinopathy, glucose-6-phosphate 
dehydrogenase (G6PD) deficiency, hookworm infestation and 
leukaemia. In most cases, these factors tend to co-exist.1
Severe anaemia-related deaths continue to occur in many centres 
in the tropics, even where blood transfusion services are readily 
available.1,2 To limit this mortality, we studied children admitted 
with severe anaemia in a newly established tertiary health centre 
requirements for POC positioning of Xpert exceeded expectations. 
As a result, the responsibilities transferred from laboratory to clinic 
went beyond sample processing. The magnitude of the challenges 
will be highly dependent on the existing infrastructure and current 
organisation of TB diagnosis and treatment facilities. Programmes will 
therefore need to carefully weigh the benefits against infrastructural 
and human resource needs when deciding on a POC or laboratory 
policy for implementation of Xpert MTB/RIF. 
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Determinants of mortality in Nigerian children 
with severe anaemia
Samuel Adegoke, Adenike Ayansanwo, Isaac Oluwayemi, John Okeniyi
Background. Severe anaemia (haemoglobin concentration <50 g/l) is a 
major cause of paediatric hospital admissions and deaths in the tropics.
Objectives.To examine the pattern and predictors of mortality 
among severely anaemic children.
Methods. A prospective cross-sectional study was conducted 
among children with severe anaemia at the Children’s Emergency 
Room of the University Teaching Hospital, Ado-Ekiti, Nigeria. Socio-
demographic characteristics, clinical features, laboratory findings and 
co-morbidities of the survivors and those who died were compared by 
logistic regression analysis.
Results. Of the 1 735 children admitted, 311 (17.9%) had severe 
anaemia, with a case-fatality rate of 9.3%. The presence of respiratory 
distress (95% confidence interval (CI) 2.1 - 3.6, p=0.031); acidosis 
(95% CI 1.8 - 2.7, p=0.010); coma (95% CI 0.1 - 0.3, p=0.001); 
hypotension (95% CI 2.0 - 4.2, p=0.020); and bacteraemia (95% CI 3.1 
- 3.9; p=0.008) were the significant independent predictors of death 
with regression analysis.
Conclusion. Early recognition with prompt and appropriate 
anticipatory intervention is essential to reduce mortality from severe 
anaemia.
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